250 related articles for article (PubMed ID: 16000843)
1. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.
Kimura N; Watanabe T; Noshiro T; Shizawa S; Miura Y
Endocr Pathol; 2005; 16(1):23-32. PubMed ID: 16000843
[TBL] [Abstract][Full Text] [Related]
2. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
[TBL] [Abstract][Full Text] [Related]
3. Differential diagnosis of pheochromocytomas and paragangliomas.
McNichol AM
Endocr Pathol; 2001; 12(4):407-15. PubMed ID: 11914474
[TBL] [Abstract][Full Text] [Related]
4. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
[TBL] [Abstract][Full Text] [Related]
5. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
[TBL] [Abstract][Full Text] [Related]
6. Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas.
Havekes B; van der Klaauw AA; Weiss MM; Jansen JC; van der Mey AG; Vriends AH; Bonsing BA; Romijn JA; Corssmit EP
Endocr Relat Cancer; 2009 Jun; 16(2):527-36. PubMed ID: 19289533
[TBL] [Abstract][Full Text] [Related]
7. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
[TBL] [Abstract][Full Text] [Related]
8. Histological features, Ki-67 and Bcl-2 immunohistochemical expression and their correlation with the aggressiveness of pheochromocytomas.
Jovanovic R; Kostadinova-Kunovska S; Bogoeva B; Spasevska L; Petrusevska G
Prilozi; 2012; 33(2):23-40. PubMed ID: 23425867
[TBL] [Abstract][Full Text] [Related]
9. Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas.
McNicol AM
Endocr Pathol; 2006; 17(4):329-36. PubMed ID: 17525481
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of human telomerase catalytic subunit mRNA by in situ hybridization in pheochromocytomas.
Luo Z; Li J; Qin Y; Ma Y; Liang X; Xian J; Lu D; Wei M; Yang JY; Yang MQ; He Z
Endocr Pathol; 2006; 17(4):387-98. PubMed ID: 17525487
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas.
Guo D; Zhao X; Wang A; Xie Q; Xu X; Sun J
Hum Pathol; 2019 Apr; 86():155-162. PubMed ID: 30594747
[TBL] [Abstract][Full Text] [Related]
12. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
[TBL] [Abstract][Full Text] [Related]
13. Growth factors and cytokines in paragangliomas and pheochromocytomas, with special reference to sustentacular cells.
Kontogeorgos G; Scheithauer BW; Kovacs K; Horvath E; Melmed S
Endocr Pathol; 2002; 13(3):197-206. PubMed ID: 12446918
[TBL] [Abstract][Full Text] [Related]
14. Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas.
Mete O; Tischler AS; de Krijger R; McNicol AM; Eisenhofer G; Pacak K; Ezzat S; Asa SL
Arch Pathol Lab Med; 2014 Feb; 138(2):182-8. PubMed ID: 24476517
[TBL] [Abstract][Full Text] [Related]
15. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of tenascin in pheochromocytomas correlates with malignancy.
Salmenkivi K; Haglund C; Arola J; Heikkilä P
Am J Surg Pathol; 2001 Nov; 25(11):1419-23. PubMed ID: 11684959
[TBL] [Abstract][Full Text] [Related]
17. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience.
Ayala-Ramirez M; Feng L; Habra MA; Rich T; Dickson PV; Perrier N; Phan A; Waguespack S; Patel S; Jimenez C
Cancer; 2012 Jun; 118(11):2804-12. PubMed ID: 22006217
[TBL] [Abstract][Full Text] [Related]
18. [Tumors of the adrenal medulla and the paraganglia].
Klöppel G
Pathologe; 2003 Jul; 24(4):280-6. PubMed ID: 14513275
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical Expression of Choline Acetyltransferase and Catecholamine-Synthesizing Enzymes in Head-and-Neck and Thoracoabdominal Paragangliomas and Pheochromocytomas.
Kimura N; Shiga K; Kaneko KI; Oki Y; Sugisawa C; Saito J; Tawara S; Akahori H; Sogabe S; Yamashita T; Takekoshi K; Naruse M; Katabami T
Endocr Pathol; 2021 Dec; 32(4):442-451. PubMed ID: 34743284
[TBL] [Abstract][Full Text] [Related]
20. [Pheochromocytomas in adrenal medulla or extra-adrenal and multiple endocrine neoplasms:a clinicopathologic analysis of 181 cases].
Jiang CX; Zeng Z; Wang T; Liu X; Liu R; Li Y
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):762-6. PubMed ID: 22336161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
